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Background: Endothelial dysfunction, largely dependent on impaired nitric oxide bioavailability, has been
reportedly associated with incident type 2 diabetes. Our aim was to test the hypothesis that asymmetric
dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide formation, might be linked to future deterioration
in glucose tolerance in stable coronary artery disease (CAD).
Methods: We studied 80 non-diabetic men (mean age 55 ± 11 years) with stable angina who underwent successful
elective complex coronary angioplasty and were receiving a standard medication according to practice guidelines.
Plasma ADMA and its structural isomer symmetric dimethylarginine (SDMA) were measured prior to coronary
angiography. An estimate of insulin resistance by homeostasis model assessment (HOMA-IR index) was calculated
from fasting insulin and glucose. Deterioration in glucose tolerance was defined as development of type 2 diabetes
or progression from a normal glucose tolerance to impaired fasting glucose.
Results: Over a median follow-up of 55 months 11 subjects developed type 2 diabetes and 13 progressed to
impaired fasting glucose. Incident deterioration of glucose tolerance was associated with ADMA (hazard ratio [HR]
per 1-SD increment 1.64 [95% CI: 1.14–2.35]; P = 0.007), log (HOMA-IR index) (HR = 1.60 [1.16–2.20]; P = 0.004) and
body-mass index (HR = 1.44 [0.95–2.17]; P = 0.08) by univariate Cox regression. ADMA (HR = 1.65 [1.14–2.38];
p = 0.008) and log (HOMA-IR index) (HR = 1.55 [1.10–2.17]; P = 0.01) were multivariate predictors of a decline in
glucose tolerance. ADMA and SDMA were unrelated to body-mass index, HOMA-IR index, insulin or glucose.
Conclusions: ADMA predicts future deterioration of glucose tolerance independently of baseline insulin resistance
in men with stable CAD. Whether this association reflects a contribution of endothelial dysfunction to accelerated
decline of insulin sensitivity, or represents only an epiphenomenon accompanying pre-diabetes, remains to be
elucidated. The observed relationship might contribute to the well-recognized ability of ADMA to predict
cardiovascular outcome.
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Endothelial dysfunction, a predecessor of atherosclerotic
plaques and adverse cardiovascular (CV) events, is largely
mediated by depressed bioavailability of nitric oxide (NO)
[1]. Biochemical markers of endothelial activation [2-4] and
impaired endothelium-dependent vasodilation [5] have also
been identified as predictors of new-onset type 2 diabetes* Correspondence: surdacki.andreas@gmx.net
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reproduction in any medium, provided the orindependently of the degree of insulin resistance (IR) [2,5],
a major precursor of non-insulin-dependent diabetes [6-9]
and coronary atherosclerosis progression [10,11].
The endogenous inhibitor of NO formation, asymmetric
dimethylarginine (ADMA), is associated with endothelial
dysfunction and adverse outcome predictor including all-
cause mortality and CV events in patients with coronary
artery disease (CAD) and in the general population [12].
Mittermayer et al. [13] identified elevated ADMA but not
IR as an independent predictor for deterioration in glucose
tolerance in women with a history of previous gestationall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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no other reports on the association between endogenous
dimethylarginines and incident type 2 diabetes. In addition,
there are conflicting data on relations between ADMA and
the magnitude of IR in human studies [14-23].
Therefore, our aim was to test the hypothesis that
plasma ADMA levels might be linked to a future decline
of glucose tolerance in men with stable CAD.
Methods
Patients
We studied the previously characterized group of 80 non-
diabetic men with stable angina who underwent successful
elective complex coronary angioplasty with implantation of
≥1 bare-metal stent in our tertiary care center due to the
presence of a diameter stenosis of ≥70% of ≥1 major epicar-
dial artery segment [24,25]. Prior to the hospitalization, the
patients were on low-dose aspirin, angiotensin-converting
enzyme inhibitors (ACEI) and statins for ≥3 months and
this medication was maintained after discharge and sup-
plemented by clopidogrel following current practice guide-
lines (Tables 1 and 2). As described [24], exclusion criteriaTable 1 Baseline patients’ characteristics by incident deterior
Variable Deterioration in glucose tolerance
Age (years) 57 ± 11
BMI (kg/m2) 28.1 ± 4.1
Current smokers, n (%) 5 (21%)
one-vessel/multivessel CAD, n (%) 5/19 (21/79%)
Left ventricular ejection fraction (%) 71 ± 6
Hypertension, n (%) 20 (83%)
Mean blood pressure (mm Hg) 95 ± 8
Estimated GFR (mL/min per 1.73 m2) 71 ± 10
LDL cholesterol (mmol/L) 2.5 ± 0.8
HDL cholesterol (mmol/L) 0.8 ± 0.3
Triglycerides (mmol/L) 1.5 ± 0.8
Hs-CRP (mg/L) 1.9 (0.6–9.1)
Fasting glucose (mmol/L) 6.0 ± 0.8
Fasting insulin (μU/ml) 13.5 (4.9–50.2)
HOMA-IR index 3.50 (1.78–13.8)
ADMA (μmol/L) 0.53 ± 0.14
SDMA (μmol/L) 0.64 ± 0.15
L-arginine (μmol/L) 68 ± 19
Drugs besides aspirin + ACEI + statin
β-blockers, n (%) 17 (71%)
Long-acting nitrates, n (%) 23 (96%)
Calcium channel blockers, n (%) 8 (33%)
Data are shown as mean ± SD, median (range) or n (%).
* By Student’s t-test for log-transformed data.
† By Welch’s t-test for unequal variances.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ADMA, asymmetric
glomerular filtration rate; HDL, high-density lipoproteins; HOMA-IR, homeostasis mo
protein; LDL, low-density lipoproteins; SDMA, symmetric dimethylarginine.included diabetes (by either fasting glucose or postload gly-
cemia during an oral glucose tolerance test (OGTT)),
proteinuria, estimated glomerular filtration rate (eGFR)
<30 mL/min per 1.73 m2 body-surface area, any surgery
within past 6 months, acute coronary syndromes within
past 3 months, depressed left ventricular ejection fraction
(by ultrasound), heart failure, uncontrolled hypertension,
overt extracoronary atherosclerosis, chronic coexistent
diseases, infections within previous 2 months, relevant ab-
normalities in routine laboratory assays and any chronic
non-CV medication. Out of 358 potentially eligible con-
secutive patients, 275 were eliminated by the exclusion
criteria and 3 due to the discontinuation of ACEI or statins
during the follow-up, as indicated previously [24,25].
The study was conducted in compliance with the Decla-
ration of Helsinki; the ethical committee of our university
had approved the protocol and informed consent was
obtained from each patient.
Biochemical assays
Blood samples for extended biochemical assays were
drawn from an antecubital vein after an overnight fast atation in glucose tolerance
(n = 24) No deterioration in glucose tolerance (n = 56) P value
54 ± 10 0.32
26.6 ± 3.4 0.11
15 (27%) 0.57
16/40 (29/71%) 0.47
70 ± 5 0.49
42 (75%) 0.42
96 ± 9 0.85
68 ± 12 0.26
2.6 ± 0.7 0.79
0.9 ± 0.4 0.22
1.3 ± 0.7 0.40
1.6 (0.5–8.6) 0.16*
5.7 ± 0.8 0.17
12.4 (5.3–43.5) 0.04*
3.06 (1.44–10.7) 0.03*
0.46 ± 0.10 0.02†
0.68 ± 0.13 0.27
67 ± 20 0.86
45 (80%) 0.35
50 (89%) 0.34
15 (27%) 0.55
dimethylarginine; BMI, body-mass index; CAD, coronary artery disease; GFR,
del assessment for insulin resistance; Hs-CRP, high-sensitivity C-reactive
Table 2 Cardiovascular drugs used during the follow-up period*
Drug class, n (%) Deterioration in glucose tolerance (n = 24) No deterioration in glucose tolerance (n = 56) P value
Diuretics 6 (25%) 15 (27%) 0.87
β-blockers 19 (79%) 50 (89%) 0.23
α1-blockers 5 (21%) 11 (20%) 0.91
Calcium channel blockers 10 (42%) 19 (34%) 0.51
Angiotensin receptor antagonists 2 (8%) 3 (5%) 0.61
Long-acting nitrates 9 (38%) 20 (36%) 0.88
* Besides low-dose aspirin, angiotensin-converting enzyme inhibitors, statins and clopidogrel.
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angiography. Plasma (collected from ethylenedia-
minetetraacetic acid-anticoagulated blood) and serum
were separated and stored at −70°C until assayed
[24,25]. Routine analyses included complete blood count,
lipids, glucose, and creatinine using standardized labora-
tory techniques. We calculated eGFR by the simplified
formula developed by the Modification of Diet in Renal
Disease Study Group [26].
In addition, high-sensitivity C-reactive protein (hs-CRP)
and homocysteine were measured by chemiluminescent
immunoassay systems (Immulite 1000 and Immulite 2000,
DPC, Flanders, NJ, USA). A measure of IR by the homeo-
stasis model assessment (HOMA-IR index) was calculated
as a product of fasting plasma levels of insulin (μU/mL)
and glucose (mmol/L) divided by 22.5 [27].
Plasma ADMA and SDMA were determined by means
of commercially available enzyme-linked immunosorbent
assays (ELISA) (DLD Diagnostika GmbH., Hamburg,
Germany), previously validated against high-performance
liquid chromatography coupled to mass spectrometry, the
golden standard for the determination of ADMA levels
[28]. According to the manufacturer, the lower detection
limit was 0.05 μmol/L for both analytes and intra-assay
and inter-assay coefficients of variation averaged 7.5 and
10.3% (ADMA) and 6.1 and 9.8% (SDMA), respectively
[24]. Cross-reactivity with L-arginine and other methy-
larginines was <0.01–0.02% (SDMA or ADMA vs.
L-arginine), 0.44 − 1.2% (ADMA vs. SDMA), and 0.7–1.0%
(SDMA or ADMA vs. NG-monomethyl-L-arginine). L-
arginine was also measured by ELISA (DLD Diagnostika
GmbH., Hamburg, Germany); the lower detection limit
was 3.0 μmol/L and intra-assay and inter-assay coefficients
of variation averaged 3.6 and 8.3%, respectively, and cross-
reactivity 0.01% (ADMA) and 0.68% (SDMA) as described
by the manufacturer.
Collection of follow-up data
After discharge from our center the patients were
contacted directly at routine control visits in our out-
patient clinic or by telephone for the occurrence of de-
terioration of glucose tolerance that was then confirmed
by the review of hospital charts or other medical recordsand the date of diagnosis was ascertained. The personnel
involved in the collection of follow-up data were un-
aware of patients’ laboratory background.
In agreement with the 2003 recommendations of the
American Diabetes Association [29], diabetes was diag-
nosed in the presence of a fasting venous plasma glucose
≥7 mmol/L or casual plasma glucose ≥11.1 mmol/L in a
patient with classic symptoms of hyperglycemia, a fasting
venous plasma glucose ≥7 mmol/L confirmed by repeat
testing if the diagnosis was not clear on clinical grounds,
or introduction of insulin or an oral hypoglycemic drug.
Impaired fasting glucose (IFG) and normal glucose toler-
ance were defined as fasting glucose of 5.6–6.9 mmol/L
and <5.6 mmol/L, respectively [29]. As results of an OGTT
during the follow-up were available only in 20 men, exclu-
sively IFG was classified as pre-diabetes to avoid a bias
caused by the lack of repeated OGTT over time. Deterior-
ation in glucose tolerance was defined as progression from
a normal glucose tolerance to IFG or development of type
2 diabetes irrespective of baseline glucose tolerance status.
Exclusively a documented decline in glucose tolerance in
stable clinical conditions (e.g., not during a hospitalization
due to an acute coronary syndrome) was classified as an
outcome event.
Statistical analysis
Data are presented as means ± SD for continuous variables
with normal distribution, medians and range or interquar-
tile range for not normally distributed parameters, and
numbers (proportions) for categorical variables. The ac-
cordance with a normal distribution was confirmed by the
Kolmogorov-Smirnov test and uniformity of variance by
Levene’s test. Natural logarithmic transformation was ap-
plied for fasting insulin, HOMA-IR index and hs-CRP to
get a normal distribution. Additionally, log (HOMA-IR
index) was entered into further analyses due to its better
ability to predict the glucose clamp-derived reference
measure of insulin sensitivity compared to untransformed
values exhibiting a right-skewed distribution [30].
Intergroup comparisons of normally distributed para-
meters between patients with a stable and deteriorated
glucose tolerance were performed by the 2-sided Student’s
t-test or Welch’s t-test in case of the lack of homogeneity
Figure 1 Cumulative proportion survival without deterioration
in glucose tolerance according to baseline plasma asymmetric
dimethylarginine (ADMA).
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test. Bivariate relations between continuous data were
assessed by Pearson’s correlation coefficients (r).
Predictors of the risk of a decline in glucose tolerance
(outcome event) were estimated by event-free survival
analysis with the last contact with the patient treated
as a censored event if no change in glucose tolerance
status was recorded. We have not applied a competing
risk modeling approach due to a low number of deaths
(n = 3) in our study group. Kaplan-Meier event-free
survival curves were compared by the log-rank test with
ADMA levels categorized according to the median (0.45 -
μmol/L) because a preliminary analysis revealed no
significant differences between respective curves for the
first and second quartile of ADMA concentrations. Cox
proportional hazards regression was performed after
validating the proportionality assumption, i.e., the lack
of a significant effect of the interaction term between
each covariate and time, when added into regression
models. Interaction within pairs of covariates were esti-
mated by calculating the significance for respective inter-
action terms. Independent determinants of deterioration
in glucose tolerance were identified by multivariate Cox
method including only covariates for which the P value at
a univariate analysis did not exceed 0.15. Due to the col-
linearity between log-transformed values of insulinemia
and HOMA-IR index (r = 0.96, P < 0.0001), exclusively the
latter was entered into the Cox regression models. Mean
standardized hazard ratios (HR) (per 1-SD increments in
predictor variables), their 95% confidence intervals (CI)
and associated P values were shown. Analyses were
performed using STATISTICA (data analysis software
system, version 10.0.1011.0; StatSoft, Inc., Tulsa, OK,
USA). A P value <0.05 was inferred significant.
Results
Over a median follow-up of 55 months (interquartile
range 45–60 months) 11 subjects developed diabetes
and further 13 progressed to IFG from a normal glucose
tolerance. Compared to the patients with unchanged
glucose tolerance status, those with deteriorated glucose
tolerance exhibited significantly higher fasting insulin
levels, HOMA-IR index and ADMA concentrations at
baseline as well as insignificant tendencies towards a
higher body-mass index (BMI), fasting glucose and hs-
CRP (Table 1). There were no significant intergroup
differences in L-arginine or SDMA levels (Table 1). CV
drugs used during the follow-up period were similar
among the both groups (Table 2).
Pooling both groups together, SDMA correlated to
eGFR (r = −0.66, P < 0.001) and BMI to log-transformed
values of HOMA-IR index (r = 0.37, P = 0.001) and of
fasting insulin (r = 0.30, P = 0.007). Except for an insignifi-
cant tendency to a negative correlation between SDMAand log (HOMA-IR index) (r = −0.18, P = 0.12), plasma
dimethylarginines were unrelated to BMI, HOMA-IR
index, fasting insulin or glucose levels (P > 0.3).
A depressed event-free survival was observed in the
presence of an over-median ADMA level (P = 0.03 by the
log-rank test) (Figure 1). Kaplan-Meier curves data have
been shown in detail [see Additional file 1]. According to
a univariate Cox regression, ADMA (HR = 1.64 [95% CI:
1.14–2.35]; P = 0.007) and log (HOMA-IR index) (HR =
1.60 [1.16–2.20]; P = 0.004) were associated with a signifi-
cantly higher risk of deterioration in glucose tolerance,
whereas a weaker respective relationship was found
for BMI (HR = 1.44 [0.95–2.17]; P = 0.08). Neither SDMA
(P = 0.4) nor L-arginine (P = 0.9) was related to the risk of
progressive impairment of glucose tolerance. By a multi-
variate approach, ADMA and log (HOMA-IR index) were
the only significant independent predictors of a decline in
glucose tolerance (Table 3).
Discussion
Our salient finding was an association between higher
ADMA and future deterioration of glucose tolerance, ir-
respective of the degree of baseline IR, in men with
stable CAD over an about 4.5-year follow-up.
Endothelial dysfunction as a precursor of type 2 diabetes
in previous clinical reports
Our results extend previous reports suggestive of an asso-
ciation between incident type 2 diabetes and biochemical
indices of endothelial activation [2-4] or vasodilatory endo-
thelial dysfunction [5], which retained significance upon
multivariate adjustment including the HOMA-IR index [5]
or fasting insulinemia [2], surrogate markers of IR. This as-
sociation was interpreted as a possible consequence of an
impaired insulin ability to stimulate blood flow via the L-
arginine–NO pathway in the skeletal muscle and adipose
Table 3 Multivariate Cox regression analysis of the risk of incident decline of glucose tolerance
Variable SD Multivariable-adjusted* HR per 1-SD increment
Mean HR 95% CI P value
ADMA 0.115 μmol/L l.65 1.14–2.38 0.008
log (HOMA-IR index) 0.325 1.55 1.10–2.17 0.01
BMI 3.60 kg/m2 1.12 0.72–1.74 0.62
* Adjusted for the remaining covariates listed in the Table.
Abbreviations: CI, confidence interval; SD, standard deviation; HR, hazard ratio; other abbreviations as in Table 1.
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capillary level with dysfunctional endothelium as an under-
lying cause of IR [2,3,31]. That adjustment for baseline in-
sulin sensitivity (derived from the frequently sampled
intravenous glucose tolerance test) only slightly attenuated
the relationship between CV risk factors and a 5-year cu-
mulative incidence of type 2 diabetes in 872 participants of
the Insulin Resistance Atherosclerosis Study [32], is also in
keeping with the predominant role of endothelial dysfunc-
tion with regard to the risk of developing diabetes. Given
anti-inflammatory properties of the normal endothelium,
this concept is also concordant with a joint synergistic con-
tribution of higher hs-CRP and peripheral microvascular
endothelial dysfunction, but not IR, to the risk of new-
onset type 2 diabetes [5]. Admittedly, we observed no
significant association between deteriorating glucose toler-
ance and hs-CRP in contrast to some previous reports
[3,5,33]. Nevertheless, those studies were dealing with
mainly untreated subjects, whereas at the time of blood
collection our patients were chronically receiving statins,
known to decrease CRP levels [34] but not ADMA [35],
which might have obscured the discussed relationship. An
analogous mechanism, in addition to the ability of ACEI,
administered to all our subjects, to lower ADMA concen-
trations [36], could also be responsible for the lack of cor-
relation between ADMA and hs-CRP. It is noteworthy that
ADMA and hs-CRP were positively interrelated in the par-
ticipants of the Ludwigshafen Risk and Cardiovascular
Health study [37] but not the AtheroGene study [38], both
of which were focused on CAD subjects presenting mainly
stable angina.
Associations between the L-arginine–NO–ADMA pathway
and insulin signaling
Sydow et al. [39] reported enhanced whole-body insulin
sensitivity in transgenic mice overexpressing dimethy-
larginine dimethylaminohydrolase (DDAH), an enzyme
responsible for the predominant pathway of ADMA deg-
radation [40]. Moreover, a more effective insulin signaling
in the liver and a trend for increased baseline glucose up-
take in an isolated fast-twitch muscle were observed. Add-
itionally, in wild-type animals low ADMA levels (2 μmol/L)
impaired insulin-mediated glucose uptake and incorpor-
ation of glucose into glycogen in an isolated fast-twitch
muscle but not a slow-twitch muscle [39]. Furthermore, afunctional variant of the DDAH-2 gene, linked to depressed
expression of the isoform of DDAH which predominates in
the vascular endothelium [40], was associated with a higher
IR in 1,485 non-diabetic subjects of European ancestry, out
of whom 527 had insulin sensitivity assessed as insulin-
stimulated glucose disposal rate during the last hour of a
hyperinsulinemic euglycemic clamp, the golden standard
method [22]. According to Baron and colleagues [41],
a superimposed intrafemoral artery infusion of NG-
monomethyl-L-arginine during hyperinsulinemic euglycemic
clamps not only abolished the insulin-dependent NO-
mediated vasodilation [42,43] but also reduced leg glucose
uptake. Thus, besides impaired hepatic insulin signaling,
the ADMA-mediated inhibition of glucose uptake by the
skeletal muscles – in part dependent on the blockade of
vascular endothelial-type NO synthase (eNOS) and conse-
quently blunted muscular perfusion under hyperin-
sulinemic conditions [41-43] – might have contributed to
the relations between DDAH-2 polymorphism and dia-
betes incidence or IR [22], providing also a mechanistic
explanation for our findings.
Additionally, a modulation of neuronal-type NO syn-
thase (nNOS), whose variant is expressed predominantly in
fast-twitch skeletal muscle fibers [44], might be responsible
for the association between IR and the L-arginine–NO
pathway. It is noteworthy that although both nNOS-
knockout and eNOS-deficient mice were insulin-resistant
compared to wild-type animals, the former exhibited IR ex-
clusively at the level of peripheral tissues, whereas in the
latter IR was present also in the liver [45]. Furthermore, a
polymorphism of the gene encoding DDAH-1, an iso-
form of DDAH tending to accompany nNOS [40], was
associated with both a decreased risk of type 2 diabetes
and a tendency towards a lower HOMA-IR index in 814
Taiwanese subjects [46].
ADMA levels versus the magnitude of IR in clinical
conditions
Although the presented experimental and genetic data
suggest reciprocal and stimulatory interactions between
the L-arginine-NO pathway and metabolic sensitivity to
insulin [22,39,41,45,46], there are conflicting reports on
the relationship between ADMA and IR in clinical condi-
tions [13-23]. Intriguingly, we detected no correlation be-
tween ADMA and the HOMA-IR index, in accordance
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independent relationship between higher ADMA levels
14–16 weeks after delivery with future deterioration of
glucose tolerance in 18 out of 77 women with previous
gestational diabetes mellitus who progressed to impaired
glucose tolerance in 9 and developed new-onset type 2
diabetes in further 9 cases after a median follow-up of al-
most 3 years. The lack of association between ADMA and
the magnitude of IR was also observed by other authors,
including ourselves [14,18-20], in contrast to studies
reporting a positive relationship between the respective
parameters [15-17,21,23]. Admittedly, the absence of posi-
tive correlations between ADMA and the HOMA-IR
index or BMI in our subjects – in disagreement with a
large study [23] – might have resulted from a relatively
low inter-individual variability of ADMA values. Neverthe-
less, there are also inconsistent data on the effects of
rosiglitazone, an insulin-sensitizing agent, on ADMA
levels [15,47].
Ferrannini et al. [9] demonstrated that deterioration of
glucose tolerance over time was associated with longitu-
dinal decreases in both insulin sensitivity and β-cell sensi-
tivity to glucose. Thus, given IR as the primary determinant
of future development of type 2 diabetes [6-9], the present
study suggests that endothelial dysfunction and higher
ADMA might rather predispose to further potentiation of
IR without an unequivocal association with IR at baseline
in cross-sectional analyses [13-23]. Additionally, we cannot
exclude the possibility that ADMA might progressively
impair β-cell function, another contributor to the develop-
ment of type 2 diabetes [6-9].
Mechanistic considerations
Admittedly, a correlation does not imply a cause-and ef-
fect relationship and elevated ADMA might be only an
epiphenomenon accompanying some abnormalities in the
pre-diabetic state. These abnormalities can include higher
glucose levels, a well-recognized cause of elevated ADMA
via depressed DDAH activity due to a higher intracellular
oxidative stress [48]. Additionally, the hyperglycemia-
induced depression of DDAH activity [48] might counter-
act the hyperinsulinemia-stimulated uptake of ADMA
into the cells via an augmented expression of cationic
amino acid transporters (CAT) [49]. A complex interplay
between these opposite effects of glucose and insulin on
plasma ADMA [50] might be responsible for the previ-
ously mentioned discordant reports on the relationship
between IR and ADMA [13-23]. Moreover, the same
opposing regulatory mechanisms could also explain nega-
tive correlations between the HOMA-IR index and the
SDMA/ADMA ratio [19] or SDMA [20] in Caucasians,
an insignificant tendency to which was also found in
our study group. Accordingly, the hyperinsulinemia-
stimulated CAT-dependent uptake of ADMA and SDMAinto the cells, probably within the liver and the kidney
(both referred to as a “sink” for circulating ADMA [50]) –
might hypothetically be counteracted – for ADMA but
not SDMA – by the hyperglycemia-induced depression of
DDAH activity [48]. In agreement with this concept,
insulin-resistant subjects are prone to hyperinsulinemia
and hyperglycemia and Eid et al. [51] reported a fall in
ADMA during acute euglycemic hyperinsulinemia in
humans. It is noteworthy that these two apparently con-
trary effects of insulin and glucose in terms of extracellular
ADMA are likely to converge into increased intracellular
ADMA levels [50]. Thus, the lack of relationship between
plasma ADMA and HOMA-IR index, as in the present
study, does not exclude the hypothetical continuous
modulation of insulin signaling by intracellular ADMA.
Another interfering factor could be hepatic ability to
clear plasma from endogenous dimethylarginines, respon-
sible for about 30% and 20% of the combined hepatic and
renal uptake of ADMA and SDMA in humans, respec-
tively [52]. DDAH-1 expression was reduced during
diabetogenesis in the liver, kidney and adipose tissue of
mice with a point mutation in leptin receptor, an experi-
mental motel of type 2 diabetes [53]. However, whether
similar abnormalities occur in human pre-diabetic sub-
jects, is as unclear as their speculative relevance for circu-
lating ADMA levels or the risk of developing type 2
diabetes.
Clinical implications
That our CAD subjects were receiving a standard thera-
peutic regimen in agreement with current guidelines,
may point into a potential relevance of our results for
the clinical reality. As progressive impairment of glucose
tolerance is associated with a continuous rise in CV risk
until its highest values in overt diabetes [54], the ob-
served relation between elevated ADMA and a decline
in glucose tolerance might contribute to the detrimental
effect of ADMA on CV outcome [12,37,38]. Further-
more, Rijkelijkhuizen et al. [55] suggested conversion to
type 2 diabetes as a basis of an excessive future CV mor-
tality in Hoorn study participants exhibiting IFG. There-
fore, besides the well-recognized link between ADMA
and endothelial dysfunction [56], our finding might add
to novel putative mechanisms of detrimental ADMA ef-
fects, e.g. its association with elevated arterial stiffness
[57] or increased plasma viscosity [58] described in pre-
diabetes and dyslipidemia, respectively. It is noteworthy
that the correlation between ADMA and arterial stiff-
ness in pre-diabetes was additive to an independent ef-
fect of low-density lipoproteins cholesterol [57]. Thus,
excessive ADMA accumulation not only accompanies
atherosclerotic risk factors, such as hypercholesterolemia
[35] and essential hypertension [14], but also appears to
amplify coexistent abnormalities.
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receptor blockers and statins – despite improving NO
bioavailability – exert opposite effects on the risk of new-
onset type 2 diabetes [59,60]. As ACEI and angiotensin
receptor antagonists are able to lower ADMA levels [36]
in contrast to the majority of reports on statins [35,40],
our observation could provide a possible rationale for
differential effects of these drug classes on the risk of de-
veloping type 2 diabetes.
Study limitations
First, the lack of repeated determinations of ADMA,
SDMA and IR over time constrains mechanistic conclu-
sions based on a single measurement of these parameters
in a relatively small number of study participants. Add-
itionally, relatively high coefficients of variation of the
ELISA assays for ADMA and SDMA pose another limita-
tion. Second, we did not assess lifestyle factors or longitu-
dinal changes in body weight, known to affect the risk of
type 2 diabetes [9]. Third, in our retrospective analysis ex-
clusively IFG was classified as pre-diabetes to avoid a bias
resulting from the fact that results of an OGTT during the
follow-up were available only in a minority of the study
subjects. Fourth, although no significant intergroup differ-
ences in the use of various CV drug classes during the
follow-up period were detected, the type of medication was
determined exclusively by the analysis of an available me-
dical documentation. Finally, IR was quantified on the basis
of an indirect measure, i.e., the log-transformed HOMA-IR
index. Nevertheless, this parameter not only exhibited a
close correlation with the glucose clamp-derived insulin
sensitivity index [30], but it also was one of the best predic-
tors of incident type 2 diabetes among surrogate estimates
of IR based on assays of fasting insulin and glucose [8].
Conclusions
Our results suggest that higher plasma ADMA levels are
associated with future deterioration of glucose tolerance
over an about 4.5-year follow-up independently of the
magnitude of baseline IR in men with stable CAD.
Whether this association reflects a contribution of endothe-
lial dysfunction to accelerated decline in insulin sensitivity,
or represents only an epiphenomenon accompanying pre-
diabetes, remains to be elucidated. The observed relation-
ship might contribute to the well-recognized ability of
ADMA to predict CV outcome.Additional file
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